Erratum: Letter to the Editor: SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival

Erratum: Letter to the Editor: SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival

Correction to: British Journal of Cancer (2010) 102, 232–233. doi: 10.1038/sj.bjc.6605446 Upon publication of this Letter to the Editor, it was noted that the affiliation for Dr Mark Nuijten had been presented incorrectly. The correct affiliation for Dr Nuijten is ‘Ars Accessus Medica in Amsterdam,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of cancer 2010-03, Vol.102 (6), p.1078-1078
Hauptverfasser: Nuijten, M, Mickisch, G
Format: Artikel
Sprache:eng
Schlagworte:
631/114/2415
631/67/1059/99
692/699/67/589/1588/1351
692/700/1750/1976
Biomedical and Life Sciences
Biomedicine
Cancer Research
corrigendum
Drug Resistance
Epidemiology
Erratum
Molecular Medicine
Oncology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Correction to: British Journal of Cancer (2010) 102, 232–233. doi: 10.1038/sj.bjc.6605446 Upon publication of this Letter to the Editor, it was noted that the affiliation for Dr Mark Nuijten had been presented incorrectly. The correct affiliation for Dr Nuijten is ‘Ars Accessus Medica in Amsterdam, Dorpsstraat 75 1546 LG, The Netherlands’.
ISSN:0007-0920
1532-1827
DOI:10.1038/sj.bjc.6605613